Kineta ( (KANT) ) just unveiled an announcement.
Kineta, Inc. and TuHURA Biosciences have entered into a non-binding letter of intent for a potential transaction where TuHURA would acquire rights to Kineta’s VISTA blocking antibody, KVA12123. This potential acquisition aligns with TuHURA’s strategy of expanding its immune-oncology pipeline, which includes novel therapies like IFx-2.0 and IFx-3.0 targeting various cancers. TuHURA aims to achieve several milestones in 2024 and 2025, including initiating Phase 3 trials and completing the acquisition, enhancing its position in the biotechnology sector.
For detailed information about KANT stock, go to TipRanks’ Stock Analysis page.